Virax Biolabs Group Limited Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

Annual and transition report of foreign private issuers pursuant to Section 13 or 15(d)

(Loss)/earnings per share

(Loss)/earnings per share

12 Months Ended

Mar. 31, 2023

Note 6 — (Loss)/earnings per share


	Year Ended March 31,
	2023			2022
(Loss)/profit for the year attributable to Virax		(5,457,494	)		(1,708,827	)
Basic (loss)/earnings per share attributable to Virax – Ordinary Shares		(0.51	)		(0.18	)
Diluted (loss)/earnings per share attributable to Virax – Ordinary Shares		(0.51	)		(0.18	)

Basic (loss)/earnings per share is calculated by dividing the (loss)/profit for the year by the weighted average number of ordinary shares in issue during the financial year.

Diluted (loss)/earnings per share

Diluted (loss)/earnings per share is calculated by adjusting the weighted average number of ordinary shares in issue during the year to assume conversion of all dilutive potential ordinary shares. The Company's basic and dilutive loss per share as of March 31, 2023 and 2022 are as follows:


	As of March 31,
	2023		2022
Weighted average number of ordinary shares used in basic income per share (Ordinary shares)		10,629,835		9,563,260
Weighted average number of ordinary shares and potential ordinary shares used as the denominator in calculating diluted (loss)/earnings per share(1)		10,629,835		9,563,260

(1)

For the years ended March 31, 2023 and 2022, potential ordinary shares are anti-dilutive, as their inclusion in the diluted loss per share calculation would reduce the loss per share, and hence have been excluded.